SUPPLEMENTARY MATERIAL

Treatment Patterns and Clinical Characteristics of Systemic Lupus Erythematosus Patients With Musculoskeletal Symptoms: A Retrospective, Observational Study

Natalia Bello,1 Julie A. Birt,1 Jennifer Workman,1 Xian Zhou,2 Jorge A. Ross-Terres,1 Michelle Petri3

1Eli Lilly and Company, Indianapolis, USA; 2Syneos Health, Morrisville, USA; 3Johns Hopkins University School of Medicine, Baltimore, USA

Corresponding author:

Natalia Bello
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, IN 46285, U.S.A
+1 317. 741. 9838
bello_natalia@lilly.com
**Table S1** Disease activity definitions and criteria.

| SLE disease pattern         | Definition                                                                 | Criteria                                                                 |
|-----------------------------|---------------------------------------------------------------------------|--------------------------------------------------------------------------|
| **Chronically active**      | Consistently active disease during a one-year period                       | • SELENA-SLEDAI Arthritis >0 at each visit during a one-year period      |
|                             |                                                                           | or                                                                      |
|                             |                                                                           | • LAI Arthralgia/Arthritis ≥1 at each visit during a one-year period      |
| **Relapsing-remitting**     | Active disease interspersed with periods of disease inactivity on one or more visits during a 1-year period | Active disease                                                           |
|                             |                                                                           | • SELENA-SLEDAI >0                                                      |
|                             |                                                                           | or                                                                      |
|                             |                                                                           | • LAI Arthralgia/Arthritis ≥1 at least once during one-year period       |
|                             |                                                                           | *Inactive Disease                                                       |
|                             |                                                                           | • SELENA-SLEDAI Arthritis=0                                              |
|                             |                                                                           | and                                                                     |
|                             |                                                                           | • LAI Arthralgia/Arthritis=0                                             |
| **Long quiescence**         | Inactive disease at all visits during a 1-year period.                    | • SELENA-SLEDAI Arthritis=0                                              |
|                             |                                                                           | and                                                                     |
|                             |                                                                           | • LAI Arthralgia/Arthritis=0                                             |

LAI=Lupus Activity Index; SELENA-SLEDAI=Safety of Estrogens in Systemic Lupus Erythematosus National Assessment- Systemic Lupus Erythematosus Disease Activity Index; SLE=systemic lupus erythematosus.
Supplementary Figure 1  Patient disposition from the Hopkins Lupus Cohort for patients included in the analysis of this study.

- SLE patients present in the database during the observation period\(^a\)
- Patients with \(\geq 1\) year with \(\geq 2\) annual visits
- Patients with a history\(^b\) of MSK involvement\(^c\)
- Patients \(\geq 18\) years old at start of observation period
- Presence of MSK involvement\(^c\) during the observation period\(^a\)

\(^a\)Observation period was January 1, 2010 to December 31, 2019.
\(^b\)History was before January 2010 or before the time entering the cohort if patient was enrolled after 2010.
\(^c\)Presence of MSK symptoms was based on SELENA-SLEDAI arthritis or LAI arthralgia/arthritis VAS score \(\geq 1\) during the observation period and based on physician assessment for presence of arthralgia/arthritis during a patient’s history for patients who entered the cohort after 2010. For patients who entered the cohort before 2010 MSK symptoms were defined using SELENA-SLEDAI, LAI, and physician assessment.

LAI=Lupus Activity Index; MSK=musculoskeletal; N=number of patients; SELENA-SLEDAI=Safety of Estrogens in Systemic Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index; SLE=systemic lupus erythematosus; VAS=visual analog scale.
Supplementary Figure 2 Proportion of time spent in each disease activity$^a$.

$^a$Patients with $\geq$2 visits during each year of observation were classified by yearly disease activity pattern.
CA=chronically active; LQ=long-quiescent; PY=person-years; RR=relapsing remitting.